Clinical trials: completed, sponsored by Jonsson Comprehensive Cancer Center
Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7, Stage II Prostate Adenocarcinoma AJCC v7
Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
This phase I trial studies stereotactic body radiation therapy (SBRT) in treating patients with prostate cancer that is likely to come back or spread (high-risk) undergoing surgery.
- Conditions
- Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT02830165
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Melanoma
Study of Gene Modified Immune Cells in Patients With Advanced Melanoma
The purpose of this phase 2 study is to find the best way to give this new experimental regimen and determine if it can treat metastatic melanoma in humans.
- Trial name
- F5 (NCT00910650)
- Testing
- F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells, non-myeloablative conditioning chemotherapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer
This phase II trial studies how well pembrolizumab works in treating patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer that have not received prior tyrosine kinase inhibitor therapy and has…
- Conditions
- Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Trial name
- NCT02879994
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Green Tea, Black Tea, or Water in Treating Patients With Prostate Cancer Undergoing Surgery
RATIONALE: Green tea contains ingredients that may prevent or slow the growth of certain cancers. It is not yet known whether green tea is more effective than black tea or water in treating prostate cancer.
- Trial name
- NCT00685516
- Testing
- green tea, decaffeinated black tea
- Where
- 2 sites in United States
- Volunteers
- 113 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Adult Diffuse Astrocytoma, Adult Mixed Glioma
Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
The primary purpose of this phase II clinical trial is to determine the safety and effect on survival of patients autologous dendritic cells pulsed with autologous tumor lysate as a treatment for low-grade glioma patients.
- Conditions
- Adult Diffuse Astrocytoma, Adult Mixed Glioma, Adult Oligodendroglioma, Recurrent Adult Brain Tumor
- Trial name
- NCT01635283
- Testing
- tumor lysate-pulsed autologous dendritic cell vaccine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Melanoma (Skin)
Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma
RATIONALE: Monoclonal antibodies, such as ticilimumab (CP-675,206), can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00471887
- Testing
- CP-675,206
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer
Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression
RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00033514
- Testing
- trastuzumab, erlotinib hydrochloride
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT01013285
- Testing
- bevacizumab, temozolomide, external beam radiation therapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer
Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00068341
- Testing
- trastuzumab, carboplatin, docetaxel
- Where
- 4 sites in United States
- Volunteers
- 74 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Kidney Cancer
Bortezomib in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00276614
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00049257
- Testing
- carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Liver Cancer
Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, cisplatin, and mitomycin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping the cells from dividing.
- Trial name
- NCT00049322
- Testing
- bevacizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00998010
- Testing
- bortezomib + temozolomide+ radiation therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Giving bortezomib as maintenance therapy after autologous stem cell transplantation may kill more cancer cells and…
- Trial name
- NCT00084747
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Lymphoma
Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well bortezomib works in treating patients with relapsed or refractory…
- Trial name
- NCT00182637
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Neoplasm, Lesion
Radiofrequency Identification Technology in Locating Non-palpable Breast Lesions in Patients Undergoing Surgery
This pilot clinical trial studies radiofrequency technology in locating non-palpable breast lesions in patients undergoing surgery.
- Trial name
- NCT03202472
- Testing
- Implanted Medical Device, Mammography, Questionnaire Administration
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center